2013-04-29 09:48 TikoMed TikoMed initiates a phase I/II study at CTC, Sahlgrenska hospital in Gothenburg. The study documents TikoMeds orphan drug, TM-400, which can improve hematopoietic stem cell transplantation for patients with hematopoietic cancer.

